Acute drug-induced interstitial lung disorders
ICD-10 J70.2 is a billable code used to indicate a diagnosis of acute drug-induced interstitial lung disorders.
Acute drug-induced interstitial lung disorders (J70.2) refer to a group of lung conditions characterized by inflammation and scarring of the lung interstitium, which can occur following exposure to certain medications. Clinically, patients may present with symptoms such as dyspnea, cough, and chest discomfort, often developing within days to weeks after drug exposure. The anatomy involved primarily includes the alveoli and interstitial spaces of the lungs, where the inflammatory process disrupts normal gas exchange. Disease progression can vary, with some patients experiencing rapid deterioration, while others may have a more insidious onset. Diagnostic considerations include a thorough patient history to identify potential drug exposures, imaging studies such as chest X-rays or CT scans to assess lung involvement, and pulmonary function tests to evaluate respiratory impairment. A lung biopsy may be necessary in some cases to confirm the diagnosis and rule out other interstitial lung diseases.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
J70.2 covers acute interstitial lung disorders induced by specific drugs, including but not limited to certain antibiotics, chemotherapeutic agents, and non-steroidal anti-inflammatory drugs (NSAIDs). Diagnostic criteria typically involve a temporal relationship between drug exposure and the onset of respiratory symptoms, along with imaging findings consistent with interstitial lung disease.
J70.2 should be used when there is clear evidence of acute interstitial lung disease linked to a specific drug exposure, differentiating it from chronic interstitial lung diseases or other respiratory conditions that may not have a drug-related etiology.
Documentation should include a comprehensive medication history, clinical symptoms, imaging results, and any laboratory findings that support the diagnosis of drug-induced lung disease. Clear correlation between the timing of drug exposure and symptom onset is crucial.
